Cinobufagin

Cat. No.: HY-N0421
CAS No.: 470-37-1
Molecular Formula: $C_{26}H_{34}O_6$
Molecular Weight: 442.54
Target: Autophagy
Pathway: Autophagy
Storage:
- Powder: -20°C, 3 years; 4°C, 2 years
- In solvent: -80°C, 6 months; -20°C, 1 month

**SOLVENT & SOLUBILITY**

**In Vitro**
DMSO: $\geq 43$ mg/mL (97.17 mM)

*“$\geq$” means soluble, but saturation unknown.*

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Mass (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Concentration</strong></td>
<td><strong>1 mg</strong></td>
</tr>
<tr>
<td>1 mM</td>
<td>2.2597 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4519 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2260 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**BIOLOGICAL ACTIVITY**

**Description**
Cinobufagin, a kind of Chinese materia medica with antitumor effect, is widely used in clinical practice, especially in anti-liver cancer. IC50 value: Target: In vitro: Cinobufagin inhibited proliferation of cancer cells at doses of 0.1, 1, or 10 μM after 2–4 days of culture. Cytotoxicity of cinobufagin on the DU145 and LNCaP cells was dose-dependent. Cinobufagin increased [Ca2+]i and apoptosis in cancer cells after a 24-hr culture as well as caspase 3 activities in DU145 and PC3 cells and caspase 9 activities in LNCaP cells [1]. Cinobufagin suppresses cell proliferation and causes apoptosis in prostate cancer cells via a sequence of apoptotic modulators, including Bax, cytochrome c and caspasases [2].

**REFERENCES**


